ArticleCureus2026
Neonatal Conjugated Hyperbilirubinemia: Clinical Profile, Etiology, and Predictors of Adverse Outcomes in a NICU of a Tertiary Care Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesNeonatal conjugated hyperbilirubinemia is a pathological condition reflecting cholestasis and hepatobiliary dysfunction, associated with significant morbidity and mortality if not detected early. Early recognition is critical, especially for surgically correctable or treatable causes such as biliary atresia and inherited metabolic liver diseases. Limited region-specific data exist from Northern India. This study aimed to characterize the clinical and biochemical profile, delineate the etiological spectrum, and identify predictors of adverse outcomes among neonates admitted to a tertiary care neonatal intensive care unit (NICU). METHODOLOGY: A prospective observational study was conducted over one year in the NICU of King George's Medical University (KGMU), Lucknow. Neonates with conjugated hyperbilirubinemia (direct bilirubin >1 mg/dL if total bilirubin ≤5 mg/dL or >20% if total bilirubin >5 mg/dL) were consecutively enrolled. Clinical, laboratory, microbiological, and imaging evaluations were performed. Outcomes were classified as good (discharged) or adverse (expired/leave against medical advice), and multivariate logistic regression identified independent predictors of poor prognosis.
resultsSeventy neonates were enrolled. Sepsis was the predominant etiology (41.4%), followed by intestinal pathology (27.1%). Multisystem involvement was frequent, with respiratory distress (91.4%), hepatomegaly (60%), encephalopathy (52.9%), and lactic acidosis (60%). Overall mortality was 50%, with 31.4% discharged. Adverse outcomes were significantly associated with elevated bilirubin, coagulopathy, hypoalbuminemia, and anemia. Independent predictors included neonatal acute liver failure (adjusted OR (aOR): 5.40; 95% CI: 2.10-11.20; p=0.0001), multiple organ dysfunction (aOR: 4.2; 95% CI:1.67-10.58; p= 0.003), metabolic disorders (aOR: 3.1; 95% CI:1.14-8.42; p=0.027), intestinal pathology (aOR:2.9; 95% CI:1.21-6.87; p=0.015), culture-positive sepsis (aOR: 2.6; 95% CI:1.14-5.98; p=0.02 ), and prolonged total parenteral nutrition (aOR: 2.3; 95% CI: 1.01-5.12; p=0.047 ).
conclusionNeonatal conjugated hyperbilirubinemia in this tertiary NICU cohort was predominantly driven by sepsis and intestinal pathology, with high mortality. Early, structured evaluation and targeted management of high-risk neonates may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.